Loading
PAQ Therapeutics makes medicines that get the cell to destroy the faulty KRAS protein that drives many bowel, pancreatic and lung cancers, rather than simply blocking it.
PAQ Therapeutics, Inc., based in Burlington, Massachusetts, develops targeted protein degraders against KRAS. PT0253 is in a phase 1 trial, alone and with chemotherapy, in advanced solid tumours with the KRAS G12D mutation (NCT06797336). PT0511, which the company describes as a pan-KRAS degrader, entered a phase 1 trial in KRAS-mutated or amplified solid tumours, with the first patient dosed by January 2026 (NCT07300150). The company announced a USD 39 million Series B in May 2025 and an extension in January 2026 bringing total Series B financing to USD 77 million. Its first registered cancer trial, NCT06797336, was posted on ClinicalTrials.gov in January 2025.
Investors not recorded; see the round sources.
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares KRAS & RAS inhibitors, PROTACs & molecular glues (targeted protein degradation), KRAS.
Shares KRAS & RAS inhibitors, KRAS.
Shares KRAS & RAS inhibitors, KRAS.
Shares KRAS & RAS inhibitors, KRAS.
Shares KRAS & RAS inhibitors, KRAS.
Shares KRAS & RAS inhibitors, KRAS.
Shares KRAS & RAS inhibitors, KRAS.
Shares KRAS & RAS inhibitors, KRAS.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/